The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aytu Bioscience (AYTU - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aytu Bioscience is a member of our Medical group, which includes 844 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AYTU is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for AYTU's full-year earnings has moved 22.53% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, AYTU has moved about 125.90% on a year-to-date basis. In comparison, Medical companies have returned an average of 1.65%. This means that Aytu Bioscience is outperforming the sector as a whole this year.
Breaking things down more, AYTU is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #77 in the Zacks Industry Rank. On average, this group has gained an average of 0.13% so far this year, meaning that AYTU is performing better in terms of year-to-date returns.
AYTU will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aytu Bioscience (AYTU - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aytu Bioscience is a member of our Medical group, which includes 844 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AYTU is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for AYTU's full-year earnings has moved 22.53% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, AYTU has moved about 125.90% on a year-to-date basis. In comparison, Medical companies have returned an average of 1.65%. This means that Aytu Bioscience is outperforming the sector as a whole this year.
Breaking things down more, AYTU is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #77 in the Zacks Industry Rank. On average, this group has gained an average of 0.13% so far this year, meaning that AYTU is performing better in terms of year-to-date returns.
AYTU will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AYTU - FREE